ArticleJournal of cardiothoracic surgery2025
A nomogram to predict prognosis of small-cell lung cancer patients in stage II based on the ninth edition of the tumor-node-metastasis staging system.
Article in Journal of cardiothoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The role of OLMALINC in small cell lung cancer progression and prognosis.Molecular and cellular biochemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundExisting prognostic models for small-cell lung cancer (SCLC) are based on previous versions of tumor-node-metastasis (TNM) staging. Therefore, this study was devoted to developing a nomogram based on the 9th TNM staging to predict the prognosis of stage II SCLC patients. This nomogram aims not only to provide a more accurate prognostic prediction for clinicians but also to assist in personalized treatment decision - making for stage II SCLC patients, which is of great significance in improving the overall survival rate and quality of life of patients.
methodsThis retrospective study collected 1250 patients diagnosed with stage II SCLC between 2004 and 2015 from the Surveillance, Epidemiology, and End Results (SEER) database. We used nomograms based on Cox proportional hazards analysis and the Kaplan Meier method to conduct the survival analysis of the selected patients. Moreover, the consistency index (C-index) was used to compare the predictive ability of nomograms based on the 8th or 9th edition TNM classification.
resultsIn light of Cox regression analysis, we respectively took six independent factors into the nomogram of classifications of two editions, including age, the kind of surgery, radiotherapy, chemotherapy, differentiation and time to treatment. The C-indices were 0.664 (SE = 0.009) and 0.666 (SE = 0.009) in nomograms based on the 8th and 9th TNM staging, respectively.
conclusionsThe predictive ability of the nomogram based on the 8th and 9th TNM staging was comparable. In addition, through our validation, the 9th edition of TNM staging system for SCLC has a slight advantage over the 8th edition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.